Anticipated Spike in Deal Activity in 2021 Makes Customized R&W Insurance Critical, Finds Lowenstein Sandler

NEW YORK–(BUSINESS WIRE)–Encouraging news about COVID-19 vaccination trials and the impending resolution of the long election process bode well for deal activity in 2021, according to M&A and insurance recovery lawyers from Lowenstein Sandler. With an anticipated increase in financial transactions, competition among insurers is also expected to heat up, making this an ideal time … [Read more…]

ImmunityBio Simulates SARS-CoV-2 Spike Protein Binding Using Molecular Dynamics

Detailed computer modeling, completed in partnership with Microsoft, explains virulence of COVID-19 and provides key information that may lead to a better understanding of the multiple mutations currently occurring to the “spike” protein as the virus evolves Computer-based molecular dynamics simulation allows highly detailed visualization of free (unbound) spike receptor binding domain (S RBD) and … [Read more…]

Vicks® Donates $1 million for COVID-19 Health Care Relief

Humanitarian Aid Organization, Direct Relief, will use the funds to deliver protective gear and essential medical aid to health care organizations CINCINNATI–(BUSINESS WIRE)–In response to the novel coronavirus (COVID-19) pandemic, the Vicks® family of cold and flu brands – NyQuil™, DayQuil™ and VapoRub™ – will donate $1 million to Direct Relief, one of the world’s … [Read more…]

Global Preclinical Medical Device Testing Services Market (2022 to 2030) – Size, Share & Trends Analysis Report – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Preclinical Medical Device Testing Services Market by Service (Biocompatibility Tests, Chemistry Test, Microbiology & Sterility Testing, Package Validation), by Region, and Segment Forecasts, 2022-2030” report has been added to ResearchAndMarkets.com’s offering. The global preclinical medical device testing services market share is expected to reach USD 4.9 billion by 2030, according to this report. … [Read more…]

Entos Pharmaceuticals Passes Significant Enrollment Milestone in Phase 2 Clinical Trial of its COVID-19 DNA Vaccine

This phase 2 trial evaluates the safety, tolerability, and immunogenicity of Covigenix VAX-001-1b in healthy adults 18 years and older A total of 268 participants have been enrolled in the study at two sites in Burkina Faso, completing the single and two-dose cohorts EDMONTON, Alberta & OUAGADOUGOU, Burkina Faso–(BUSINESS WIRE)–Entos Pharmaceuticals (Entos), a clinical-stage biotechnology … [Read more…]

Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age

NEW YORK & MAINZ, Germany–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) of a 10-µg booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children ages 5 through 11 years of … [Read more…]

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union

CHMP recommendation based on favorable data from Omicron-adapted vaccines The Omicron BA.4/BA.5 bivalent COVID-19 booster vaccine combines 15-ug of mRNA encoding the wild-type spike protein of SARS-CoV-2 in the Original Pfizer-BioNTech COVID-19 Vaccines and 15-ug of mRNA encoding the spike protein of the Omicron BA.4/BA.5 subvariants Pfizer-BioNTech bivalent Omicron BA.4/BA.5 COVID-19 vaccine is available to … [Read more…]

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union

CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2/3 trial of the Omicron BA.1-adapted bivalent vaccine The Omicron BA.1-adapted bivalent COVID-19 vaccine combines 15-µg of mRNA encoding the SARS-CoV-2 wild-type spike protein which is in the Original Pfizer-BioNTech COVID-19 Vaccine with 15-µg of mRNA encoding the spike protein of the Omicron … [Read more…]

Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older

Authorization based on clinical, pre-clinical and manufacturing data for Omicron-adapted bivalent vaccines Pfizer-BioNTech Omicron BA.4/BA.5 Bivalent Vaccine combines 15-µg of mRNA encoding the wild-type spike protein found in the Original Pfizer-BioNTech COVID-19 Vaccine and 15-µg of mRNA encoding the spike protein of the OmicronBA.4/BA.5 subvariants Pfizer-BioNTech Omicron BA.4/BA.5 COVID-19 Bivalent Vaccine available to ship immediately … [Read more…]

 Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine

Submission follows application for Omicron BA.1-adapted bivalent vaccine submitted in July If authorized, both Omicron BA.1-adapted and Omicron BA.4/BA.5-adapted bivalent vaccines will be available in the European Union as early as September NEW YORK & MAINZ, Germany–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the … [Read more…]